Exelixis files IND for cancer drug candidate XL228

By E. Janene Geiss

Philadelphia, Aug. 31 - Exelixis, Inc. said Thursday that it has submitted an Investigational New Drug application to the Food and Drug Administration for XL228, a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor, Src and Abl tyrosine kinases, targets that are crucial in cancer cell proliferation and metastasis.

Studies also show that XL228 may aid in the resistance to treatments like Gleevec (imatinib mesylate) and Sprycel (dasatanib), according to a company news release.

XL228 is the company's eighth internally discovered compound to advance to IND filing and the first of three INDs the company said it expects to file this year.

Exelixis is a South San Francisco, Calif., biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.